Refine Search
(33)
(208)
(520)
(1392)

NEW Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

  • $3,495
  • October 2019
Add to Basket Quick View Add to Saved List

Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant ...

NEW Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

  • $10,995
  • October 2019
Add to Basket Quick View Add to Saved List

Axial spondyloarthritis (axSpA) is a disease group encompassing both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). These conditions are chronic, autoinflammatory disorders of the sacroiliac joints and spin...

NEW Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2019

  • $1,500
  • October 2019
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2019” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and finan...

Deal-Making Trends in Pharma - Thematic Research

  • $1,950
  • September 2019
Add to Basket Quick View Add to Saved List

To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken...

Axial Spondyloarthritis: Epidemiology Forecast to 2028

  • $3,995
  • September 2019
Add to Basket Quick View Add to Saved List

Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on convent...

Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

  • $6,995
  • September 2019
Add to Basket Quick View Add to Saved List

Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike n...

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape -Vietnam

  • $1,995
  • September 2019
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Vietnam”. The report is an essential source of information and analysis on the healthcare, regulat...

Myasthenia Gravis: Epidemiology Forecast to 2028

  • $3,995
  • September 2019
Add to Basket Quick View Add to Saved List

Myasthenia gravis (MG) is the most common neuromuscular junction disorder, and is characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles (Lai and Tseng, 2010). In this disease...

Female Infertility: Opportunity Analysis and Forecasts to 2028

  • $10,995
  • September 2019
Add to Basket Quick View Add to Saved List

Female infertility (FI) is a complex disorder defined as the inability to conceive after at least one year of timed, unprotected intercourse. The etiology of the condition spans a wide range of disorders that can be broadly classified into the ...

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028

  • $10,995
  • September 2019
Add to Basket Quick View Add to Saved List

Ovarian cancer is a rare gynecological disease that spans a broad range of genetic and histological subtypes, for which platinum-based chemotherapy has been the standard of care (SOC) for decades. Ovarian cancer can be broken down into many dif...

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2019 in Pharmaceuticals

  • $1,000
  • September 2019
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Saudi Arabia

  • $1,995
  • August 2019
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Saudi Arabia”. The report is an essential source of information and analysis on the healthcare, re...

Alopecia Areata: Opportunity Analysis and Forecasts to 2028

  • $10,995
  • August 2019
Add to Basket Quick View Add to Saved List

Alopecia areata (AA) is the second most common non-scarring alopecia and there are no clear reasons for the onset of the condition; however, some sources have suggested that it happens as a result of genetic susceptibility from an environmental...

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

  • $10,995
  • August 2019
Add to Basket Quick View Add to Saved List

The prostate cancer market in the 8 major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) is expected to experience a moderate growth between 2018 and 2018. The main drivers of growth will be an aging population, continue...

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

  • $3,495
  • August 2019
Add to Basket Quick View Add to Saved List

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA ...

Join our mailing list
Find out first about the latest reports and offers.
Report Catalogue

Strategic Insight Reports

Market Analysis Reports

Databooks